NCT03359304

Brief Summary

Neurofibromatosis-associated Tumor is very rare bone tumor. The investigator set up the biobank to ensure every patient has the chance to participate in future research

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
22mo left

Started Mar 2018

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress82%
Mar 2018Mar 2028

First Submitted

Initial submission to the registry

November 25, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 2, 2017

Completed
3 months until next milestone

Study Start

First participant enrolled

March 1, 2018

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2023

Completed
5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2028

Expected
Last Updated

December 2, 2017

Status Verified

November 1, 2017

Enrollment Period

5 years

First QC Date

November 25, 2017

Last Update Submit

November 29, 2017

Conditions

Neurofibromatoses

Keywords

bone tumor

Outcome Measures

Primary Outcomes (1)

  • Detected NF-1 gene expression pattern in neurofibromatosis-asociated tumor

    To examine the neurofibromatosis type 1(NF-1) gene expression of the patients with neurofibromatosis-associated tumor

    3 years

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Asia

You may not qualify if:

  • non-asian

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

The investigator will collect specimen and blood. If the investigator finds out that the sample doesn't have enough cells to be useful, the investigator may call for an additional sample.

MeSH Terms

Conditions

NeurofibromatosesBone Neoplasms

Condition Hierarchy (Ancestors)

NeurofibromaNerve Sheath NeoplasmsNeoplasms, Nerve TissueNeoplasms by Histologic TypeNeoplasmsNeoplastic Syndromes, HereditaryNeurocutaneous SyndromesNervous System DiseasesHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNeoplasms by SiteBone DiseasesMusculoskeletal Diseases

Study Officials

  • Tingting Ren, phD

    Peking University People's Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kuisheng Liu, phD

CONTACT

+8601088324471tumorcenter@163.com

Study Design

Study Type
observational
Observational Model
FAMILY BASED
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Musculoskeletal Tumor Center

Study Record Dates

First Submitted

November 25, 2017

First Posted

December 2, 2017

Study Start

March 1, 2018

Primary Completion

March 1, 2023

Study Completion (Estimated)

March 1, 2028

Last Updated

December 2, 2017

Record last verified: 2017-11

Data Sharing

IPD Sharing
Will not share